Trial Design and Interventions
This was an open-label, single-arm, single-stage, and phase II study. Patients received NIRA as two 100 mg capsules (200 mg total), abiraterone acetate as four 250 mg tablets (1000 mg total) once daily, and prednisone as 5 mg tablets twice daily (10 mg total).